Published: 2021-01-29

Clinical pharmacokinetics and pharmacodynamics of vildagliptin 50 mg sustained release tablet formulation in healthy Indian males after single and multiple-dose

Alok Pote, Santhanam Ravisankar, Ganesh Sangle, Sunil Agarwal, Mohan Patil, Nitin Deshmukh, Sushil Kale, M.L.A. Baig, Viresh Yarramshetti, Khokan Debnath, Ruchi Shah, Shahu Ingole, Rishi Jain


Background: Vildagliptin 50 mg once-daily is a clinically established anti-diabetic therapy in combination with a sulphonylurea and renally impaired patients. We developed sustained release (SR) vildagliptin 50 mg tablet formulation for prolongation of dipeptidyl peptidase-4 (DPP-4) inhibition coverage. The present study compares the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of investigational vildagliptin SR 50 mg tablet with Galvus® in healthy Indian adult males after single and multiple-dose administration.

Methods: Each randomized, open-label, two-period, cross-over study enrolled 36 healthy Indian adult male subjects for the assessment of single and multiple-dose PK/PD profiles of SR 50 mg vildagliptin under fed condition. The plasma drug concentrations were quantified using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. PK parameters (Cmax (ng/ml), AUC0-18, AUC0-36, and AUC0-τ (, Tmax (hour), t1/2 (hour), Tmaxss (hour), Cτss ( were calculated using Phoenix® WinNonlin® software. The DPP-4 inhibition was determined in a fluorescence-based assay.

Results: Vildagliptin SR tablet showed prolonged PK/PD characters compared to Galvus®. All PK parameters expressed as Mean±SD. The single-dose PK measures were Cmax (58.22±11.31), AUC0-18 (556.92±135.84), AUC0-36 (608.82±159.84), Tmax (6.48±3.78). In the multiple-dose study, PK findings were Cmax (73.20±17.71), AUC0-τ (714.36±303.21), Cτss (4.15±6.51), Tmaxss (5.60±3.12). Vildagliptin SR 50 mg achieved prolonged DPP-4 inhibition (≥80%) for18-20 hours after single and multiple-dose administration as compared to Galvus® (12-13 hours).

Conclusions: Investigational vildagliptin SR tablet was found safe, well-tolerated after single and multiple-dose administration. Its extended DPP-4 inhibition profile compared to Galvus® may benefit the patient population on combination therapy with a sulphonylurea and renally impaired patients.


OSMO, Sustained release, Pharmacodynamics, Pharmacokinetics, Vildagliptin

Full Text:



Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol. 2019;10:1-10.

Mathieu C, Kozlovsk P, Paldanius PM, Foley JE, Modgill V, Evans M, et al. Clinical safety and tolerability of Vildagliptin-insights from randomised trials, observational studies and post-marketing surveillance. Eur Endocrinol. 2017;13(2):68-72.

Foley JE, Ahren B. The vildagliptin experience-25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration. Eur Endocrinol. 2017;13(2):56-61.

Del Prato S. Ten years of Vildagliptin. Eur Endocrinol. 2017;13(2):54-5.

Galvus Scientific Discussion Document EMA: 2007. Available from: Accessed: 16 July 2020.

Galvus-Summary of product characteristics: 2013; Accessed: 16th July 2020.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gubdjornsdottir S, Camisasca RP, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047-56.

He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47(5):633-64.

Hu P, Yin Q, Deckert F, Jiang J, Liu D, Kjems L, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009;49(1):39-49.

Tatosian D, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or Vildagliptin. Diabetes Ther. 2013;49(2):431-42.

Sangle GV, Patil M, Deshmukh NJ, Shengule SA, Kamble A, Vuppalavanchu KK et al. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. Eur J Clin Pharmacol. 2018;74(5):561-9.

Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006;22(10):1879-92.

Ahren B, Foley JE. The islet enhancer vildagliptin: Mechanisms of improved glucose metabolism. Int J Clin Pract. 2008;(159):8-14.

Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775-83.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidylpeptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patientswith type 2 diabetes. Clin Endocrinol Metab. 2006;91(11):4612-9.

Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosengerg M, et al. Dose proportionality and the effect of food on vildaglipttn, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007;47(9):1152-8.

Hong AR, Lee J, Ku EJ, Hwangbo Y, Kim KM, Moon JH, et al. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial. Diabetes Res Clin Pract. 2015;109(1):141-8.

Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7(6):692-8.

Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39(3):218-23.